Pembrolizumab-induced myasthenia gravis: A fatal case report

Journal of Oncology Pharmacy Practice

Volumn 24, Issue 2, 2018, Pages 146-149

  March, Katherine L ^a,b   Samarin, Michael J ^a   Sodhi, Amik ^a,b   Owens, Ryan E ^c  

^a METHODIST UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

monoclonal antibody; Myasthenia gravis; neurology; oncology; pembrolizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CEFTRIAXONE; CHOLINERGIC RECEPTOR ANTIBODY; CREATINE KINASE; IMMUNOGLOBULIN; LOSARTAN; MELOXICAM; METHYLPREDNISOLONE; PEMBROLIZUMAB; PREDNISONE; PYRIDOSTIGMINE; TAMSULOSIN; TROPONIN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; BRAIN METASTASIS; BRAIN STEM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARBON DIOXIDE TENSION; CARDIOMEGALY; CASE REPORT; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; CUTANEOUS MELANOMA; DROWSINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; EYELID DISEASE; FACE MUSCLE; FATALITY; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; HYPERCAPNIA; HYPERTENSION; IMMUNOTHERAPY; INFECTION; INTENSIVE CARE; INTERCOSTAL MUSCLE; LEUKOCYTE COUNT; LIVER METASTASIS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MAXIMAL INSPIRATORY PRESSURE; MEDICAL HISTORY; METASTATIC MELANOMA; MIDDLE AGED; MOBILIZATION; MUSCLE WEAKNESS; MYASTHENIA LIKE SYNDROME; MYOSITIS; NEPHROLITHIASIS; NEUROIMAGING; NONINVASIVE VENTILATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PERIORBITAL EDEMA; PHYSICAL EXAMINATION; PLASMAPHERESIS; PLEURA EFFUSION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; PTOSIS; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; RIGHT EYELID DROOPING; SCALP; SEROLOGY; THORAX RADIOGRAPHY; CHEMICALLY INDUCED; MYASTHENIA GRAVIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; FATAL OUTCOME; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS;

EID: 85029913538     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155216687389     Document Type: Article

References (11)

1. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007; 19: 813–824.
2. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012; 366: 2517–2519.
3. Zimmer L, Goldinger S, Hofmann L, Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016; 60: 210–225.
4. Brahmer JR, Tykodi SS, Chow LQ, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455–2455.
5. Hughes BW, Moro De Casillas ML, Kaminski HJ. Pathophysiology of myasthenia gravis. Semin Neurol 2004; 24: 21–30.
6. Lau KH, Kumar A, Yang IH, Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve 2016; 54: 157–161.
7. Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve 2016; 54: 506–507.
8. Topalian SL, Hodi FS, Brahmer JR, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2443.
9. Merck & Co., Inc. Keytruda (pembrolizumab) [package insert]. Whitehouse, NJ: Merck & Co., Inc., 2016
10. Naranjo CA, Busto U, Sellers EM, A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.
11. Johnson DB, Saranga-Perry V, Lavin PJ, Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 2015; 33: e122–e124.